Therma Bright Receives Positive Notification From U.S. DHHS's Centers for Medicare & Medicaid (CMS)
Therma Bright Receives Positive Notification From U.S. DHHS's Centers for Medicare & Medicaid (CMS)
Company anticipates CMS permanent CPT(R) and HCPCS codes in the coming days
公司預計在未來幾天內獲得CMS永久的CPT(R)和HCPCS代碼。
Toronto, Ontario--(Newsfile Corp. - August 1, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to provide a quick update from a recent notification from US Department of Health and Huma Services' (DHHS) Centers of Medicare and Medicaid (CMS). CMS has informed the Company of the pending permanent Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes for its Venowave VW5 device; anticipating notification and approval in the coming days.
多倫多,安大略省--(新聞稿--2014年8月1日)-- Therma Bright股份有限公司(TSXV:THRM)(OTCQB:TBRIF)(“Therma”或“公司”),是一家領先的、專有的診斷和醫療設備技術的開發商和投資夥伴,在最新的來自美國衛生與人類服務部(DHHS)醫療保險(CMS)的通知中,高興地向大家提供快速的更新。CMS已通知公司其Venowave VW5設備的CPT和HCPCS代碼正在審批中,並預計在未來幾天內獲得審批。
The CMS's CPT and HCPCS codes are expected to cover ten (10) health related and CMS reimbursable indications, which offers a great opportunity in the marketplace for the Company, its customers, reseller partners and shareholders. CMS will be publishing the final determinations for the 1st Biannual HCPCS Level II on this site: HCPCS Level II Coding Decisions.
CMS的CPT和HCPCS代碼預計將涵蓋十個與健康有關且可由CMS報銷的適應症,爲公司、客戶、分銷合作伙伴和股東提供了廣闊的市場機會。CMS將在此網站上發佈第一次半年度HCPCS二級編碼的最終決定。
The ten (10) indications include:
這十個適應症包括:
- Prevention of deep vein thrombosis (DVT)
- Management of the symptoms of post-thrombotic syndrome (PTS)
- Prevention of primary thrombosis
- Treatment of lymphedema
- Diminishing post-operative pain and swelling
- Treatment of leg swelling due to vascular insufficiency
- Treatment of varicose veins
- Treatment of chronic venous insufficiency
- Enhancing blood circulation
- Treatment of intermittent claudication
- 預防深靜脈血栓形成(DVT)
- 管理後血栓性綜合症(PTS)症狀
- 預防原發性血栓形成
- 淋巴水腫的治療
- 緩解術後疼痛和腫脹
- 治療由於血管功能不足引起的腿部腫脹
- 靜脈曲張的治療
- 治療慢性靜脈功能不全
- 增強血液循環
- 間歇性跛行的治療
As shared in prior releases, the Centers for Disease Control and Prevention (CDC) estimates that over 900,000 U.S. citizens are impacted by deep vein thrombosis (DVT) and pulmonary embolism (PE) alone each year. And ResearchAndMarkets global research and MarketDigital research both projected the deep vein thrombosis global market alone to reach between USD $1.26 billion by 2028 and USD 1.554 billion by 2032, respectively.
正如之前發佈的那樣,疾病控制和預防中心(CDC)估計每年僅有超過900000名美國公民受到深靜脈血栓形成(DVT)和肺栓塞(PE)的影響。ResearchAndMarkets全球研究和MarketDigital研究都預計,僅深靜脈血栓形成的全球市場在2028年將達到約12.6億美元,在2032年將達到約15.54億美元。
"We're patiently awaiting confirmation from CMS, which is expected in a matter of days," shared Rob Fia, CEO of Therma Bright. "And we plan to make the announcement and all the details around the permanent codes immediately upon receipt of this formal approval."
“我們正耐心等待CMS的確認,預計將在幾天內得到。” Therma Bright的CEO Rob Fia分享道:“我們計劃在收到正式批准的通知後立即公佈永久代碼的所有細節以及公告。”
About Therma Bright Inc.
Therma Bright Inc.簡介:Therma Bright是一家開發商和合作夥伴,在各種領先的專有診斷和醫療器械技術方面致力於爲消費者和醫療專業人士提供質量卓越,創新的解決方案,以應對當今最重要的醫療和醫療保健挑戰。在TSXV:THRM,OTCQB:TBRIF,FSE:JNX上交易。訪問:。
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
Therma Bright Inc.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
Rob Fia,首席執行官
rfia@thermabright.com
rfia@thermabright.com
關注我們的Twitter賬號
FORWARD-LOOKING STATEMENTS
前瞻性聲明
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as the commercialization of Venowave, DCA, and InStatin, and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
本新聞稿中的某些聲明構成“前瞻性”聲明。這些聲明涉及將來的事件,如在新聞稿中描述的商業化Venowave、DCA和InStatin以及相關技術。所有這類聲明都涉及大量已知和未知的風險、不確定因素和其他因素,這可能導致實際結果與所述前瞻性聲明所表達或所暗示的不同。前瞻性聲明涉及重大風險和不確定性,它們不應被視爲將來業績或結果的保證,並不一定是這樣結果的準確指標。實際結果可能因數個風險和因素而與預期結果存在差異。雖然本新聞稿中的前瞻性聲明是在本新聞稿日期管理公司相信合理的假設基礎上做出的,但公司不能保證投資者實際結果將與這些前瞻性聲明一致。本新聞稿中的前瞻性聲明是截至本文發佈日期的,公司無意或有義務更新或修訂這些前瞻性聲明,除非適用的證券法規要求。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
TSX Venture Exchange及其監管服務提供商(如TSX Venture Exchange政策中所定義)對本新聞稿的充分性或準確性不承擔責任。